ADNI Researchers and Industry Partners Developing Proteomic Profiles to Track Alzheimer's Disease
June 11, 2010
ADNI Researchers and Industry Partners Developing Proteomic Profiles to Track Alzheimer's Disease
Biotechnology firms participating in the Alzheimer's Disease Neuroimaging Initiative have received plasma and CSF samples from ADNI participants and contributed funds for the processing of roughly 1,000 samples by biomarker discovery firm Rules-Based Medicine.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Initial Analysis of ADNI Plasma Proteome Data Suggests Possible Protein Signatures for Alzheimer's
December 10, 2010 / ProteoMonitor - AD Working Group Proposes New Alzheimer's Definition to Include Protein Biomarkers
October 15, 2010 / ProteoMonitor - TARC Team Uses RBM's DiscoveryMAP Platform to Develop Alzheimer's Protein-Biomarker Test
September 17, 2010 / ProteoMonitor - Protein Biomarkers for Alzheimer's Predicted to Represent Cumulative $9B Market Over Next Decade
June 3, 2011 / ProteoMonitor - Penn Researchers ID Acetylated Tau as Potential Protein Biomarker for Alzheimer's, Related Disorders
April 8, 2011 / ProteoMonitor